<i>Lactobacillus</i> masticator abscess after probiotics consumption

Vyas, Vrinda; Mian, Sundus; Paolino, Kristopher; Siddique, Zaid

doi:10.1080/08998280.2020.1820824

Cited by 6 publications

(10 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For other nine reports, identification to the species level was not carried out and the agent of infection was designated as “ Lactobacillus spp.”. One study reported just Gram staining as the method of identification [ 54 ]. In the case of interstitial pneumonia published in 2020 ( Table 2 ) cultures were not carried out, but it was assumed that the Lactiplantibacillus paraplantarum strain present in the probiotic yogurt consumed by the patient was the cause, since ground-glass nodules (GGNs) formed in the lungs disappeared after discontinuing the assumption of the probiotic and vildagliptin [ 50 ].…”

Section: Cases Of Lactobacilli Infections Reported In Years 2019 2020...mentioning

confidence: 99%

Lactobacilli Infection Case Reports in the Last Three Years and Safety Implications

et al. 2022

View full text Add to dashboard Cite

Lactobacilli constitute the dominant microbiota in many fermented foods and comprise widely used probiotics. However, these bacteria cause rare infections mostly in diabetic and immunocompromised subjects in presence of risk factors such as prosthetic hearth valves and dental procedures or caries. The scope of this survey was re-assessing the pathogenic potential of lactobacilli based on the infection case reports published in the last three years. In 2019, 2020, and 2021, total of 17, 15, and 16 cases, respectively, including endocarditis, bacteremia, and other infections, were reported. These annual numbers are higher than those observed previously. Lacticaseibacillus rhamnosus (13 cases), comprising strain GG (ATCC 53103) with established applications in healthcare, L. paracasei (7 cases), Lactobacillus acidophilus (5 cases), L. jensenii (5 cases), Lactiplantibacillus plantarum (3 cases), L. paraplantarum, L. delbrueckii subsp. delbrueckii, L. gasseri, L. paragasseri, Limosilactobacillus fermentum, and L. reuteri (1 case each) were involved. Virulence characterization of two strains that caused infections, a derivative of L. rhamnosus GG and L. paracasei LP10266, indicated that increased biofilm-forming capacity favors pathogenicity and it is determined by variable genetic traits. This survey highlights that the strains of lactobacilli that cause infections are little characterized genetically. Instead, to avoid that these bacteria become a hazard, genetic stability should be periodically re-evaluated by whole genome sequencing (WGS) to ensure that only non-pathogenic variants are administered to vulnerable individuals.

show abstract

Section: Cases Of Lactobacilli Infections Reported In Years 2019 2020...mentioning

confidence: 99%

Lactobacilli Infection Case Reports in the Last Three Years and Safety Implications

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Lactobacilli were isolated from blood [15,16,17,18,20,21,22,23,24,25,26,27,29,30,31,32,33,34,35,36,37,38,40,41,42,43,44,45,46,47,49,52,55,56,57], diseased valve tissue [28], abscess fluids [48,51,52,54,57,58], cerebrospinal fluid (CSF) [46], marrow [36], arthrocentesis aspiration fluid [53] in anaerobiosis and, in some cases, also in aerobiosis [40,15]. Use of automated microbial detection system, i.e.…”

Section: Cases Of Lactobacilli Infections Reported In Years 2019 2020...mentioning

confidence: 99%

“…Susceptility to β-lactams, including amoxicillin, amoxicillin/clavulanic acid, ampicillin, ampicillin-sulbactam, benzylpenicillin, penicillin G, piperacillin/tazobactam and meropenem IV was reported in most cases. These antibiotics were used singly or in association with gentamicin, clindamycin and clarithromycin [16,17,20,21,22,23,24,25,26,27,31,32,33,34,36,37,38,41,43,44,45,46,48,49,51,53,54,55,56,57,58] .…”

Section: Cases Of Lactobacilli Infections Reported In Years 2019 2020...mentioning

confidence: 99%

Lactobacilli Infection Case Reports in the Last Three Years and Safety Implications

Rossi¹,

Amadoro²,

Colavita³

2022

Preprint

View full text Add to dashboard Cite

probiotics. However, these bacteria caused rare infections mostly in diabetic and immunocompromised subjects in presence of risk factors such as prosthetic hearth valves and dental procedures or caries. The scope of this survey was re-assessing the pathogenic potential of lactobacilli based on the infection case reports published in the last three years. In 2019, 2020 and 2021 17, 15 and 16 cases, respective-ly,.including endocarditis, bacteremia and other infections, were reported. These annual numbers are higher than observed previously. Lacticaseibacillus rhamnosus (13 cases), comprising strain GG (ATCC 53103) with established applications in healthcare, L. paracasei (7 cases), Lactobacillus acidophilus (5 cas-es), L. jensenii (5 cases), Lactiplantibacillus plantarum (3 cases), L. paraplantarum, L. delbrueckii subsp. del-brueckii, L. gasseri, L. paragasseri, Limosilactobacillus fermentum and L. reuteri (1 case each) were involved. Virulence characterization of two strains that caused infections, a derivative of L. rhamnosus GG and L.paracasei LP10266, indicated that increased biofilm forming capacity favors pathogenicity and it is determined by variable genetic traits. This survey highlighted that strains of lactobacilli able to cause infections were little characterized genet-ically. Instead, to avoid that these bacteria become a hazard, genetic stability should be periodically re-evaluated by whole genome sequencing (WGS) to ensure that only non-pathogenic variants are ad-ministered to vulnerable individuals.

show abstract

“…Of note, Lactobacillus infection after taking probiotics products contain Lactobacillus spp. had been reported in some relatively immunocompromised patients [ 63 , 64 , 65 ]. These immunocompromised patients were at higher risk of developing CDI, and the use of probiotics to prevent CDI in these group of patients should be approached more carefully.…”

Section: Probiotics Supply To Restore the Disturbed Microbiota In CDImentioning

confidence: 99%

Application of Microbiome Management in Therapy for Clostridioides difficile Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents

et al. 2021

View full text Add to dashboard Cite

Oral vancomycin and metronidazole, though they are the therapeutic choice for Clostridioides difficile infections (CDIs), also markedly disturb microbiota, leading to a prolonged loss of colonization resistance to C. difficile after therapy; as a result, their use is associated with a high treatment failure rate and high recurrent rate. An alternative for CDIs therapy contains the delivery of beneficial (probiotic) microorganisms into the intestinal tract to restore the microbial balance. Recently, mixture regimens containing Lactobacillus species, Saccharomyces boulardii, or Clostridium butyricum have been extensively studied for the prophylaxis of CDIs. Fecal microbiota transplantation (FMT), the transfer of (processed) fecal material from healthy donors to patients for treating CDIs, combined with vancomycin was recommended as the primary therapy for multiple recurrent CDIs (rCDIs). Either probiotics or FMT have been utilized extensively in preventing or treating CDIs, aiming at less disturbance in the microbiota to prevent rCDIs after therapy cessation. Otherwise, many newly developed therapeutic agents have been developed and aim to preserve microbiota during CDI treatment to prevent disease recurrence and might be useful in clinical patients with rCDIs in the future.

show abstract

Lactobacillus masticator abscess after probiotics consumption

Cited by 6 publications

References 7 publications

Lactobacilli Infection Case Reports in the Last Three Years and Safety Implications

Lactobacilli Infection Case Reports in the Last Three Years and Safety Implications

Lactobacilli Infection Case Reports in the Last Three Years and Safety Implications

Application of Microbiome Management in Therapy for Clostridioides difficile Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents

Contact Info

Product

Resources

About